AVI 4126

Drug Profile

AVI 4126

Alternative Names: AVI-4126; Oncomyc-NG; Resten-MP; Resten-NG

Latest Information Update: 16 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVI BioPharma
  • Developer Sarepta Therapeutics
  • Class Antineoplastics; Ischaemic heart disorder therapies; Morpholines; Urologics
  • Mechanism of Action Proto-oncogene protein c-myc modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Polycystic kidney disease
  • Discontinued Cancer; Coronary artery restenosis; Coronary disorders

Most Recent Events

  • 13 Jul 2012 AVI BioPharma is now called Sarepta Therapeutics
  • 12 Jul 2012 Discontinued - Phase-I for Coronary artery restenosis in USA (PO)
  • 12 Jul 2012 Discontinued - Phase-I for Coronary disorders in Europe (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top